At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 380 enrolled
Drug / intervention
Letrozole +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Randomized Trial to Evaluate Efficacy and Safety of Bevacizumab in Combination With Endocrine Treatment vs Endocrine Alone, in Postmenopausal With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line
In Brief
A Phase 3 clinical trial evaluating Letrozole, Bevacizumab, and 1 other intervention for Breast Cancer. Completed, enrolled 380 participants across 70 sites in 2 countries.
Detailed Summary
Locally advanced or metastatic breast cancer in postmenopausal women with negative Human Epidermal Growth Factor Receptor 2 (HER2), who are candidates for hormone treatment and who have not received previous chemotherapy or hormonotherapy for the metastatic disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesGermany, Spain
CollaboratorsHoffmann-La Roche, GBG Forschungs GmbH
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartNov 2007
Primary CompletionDec 2013
Study CompletionJul 2014
TodayJul 2026
First PostedOct 17, 2007
Enrollment StartNov 6, 2007
Primary CompletionDec 1, 2013
Study CompletionJul 24, 2014
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 18.7 years ago
Interventions
Letrozoledrug
Bevacizumabdrug
Fulvestrantdrug